GR 1015
Alternative Names: GR-1015Latest Information Update: 22 Dec 2021
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 06 Dec 2021 GR 1015 is available for licensing as of 06 Dec 2021. http://www.genequantum.com/#/common/research?pid=6&id=7&type=5
- 06 Dec 2021 Early research in Unspecified in China (Parenteral) (Suzhou GeneQuantum Healthcare pipeline, December 2021)
- 22 Jun 2021 GeneQuantum Healthcare has global patent protection for its iLDC technology platform (Suzhou GeneQuantum Healthcare pipeline, December 2021)